Last reviewed · How we verify

NeurogesX — Portfolio Competitive Intelligence Brief

NeurogesX pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NGX-4010, 8% capsaicin patch NGX-4010, 8% capsaicin patch phase 3 Topical analgesic TRPV1 Pain management
NGX-4010 NGX-4010 phase 3 Topical analgesic; TRPV1 agonist TRPV1 (transient receptor potential vanilloid 1) Pain Management / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Averitas Pharma, Inc. · 1 shared drug class
  2. Bayer · 1 shared drug class
  3. EpiCept Corporation · 1 shared drug class
  4. Express Specialty Pharmacy · 1 shared drug class
  5. Georg Kägi, MD · 1 shared drug class
  6. Grünenthal GmbH · 1 shared drug class
  7. Henry Ford Health System · 1 shared drug class
  8. Johnson & Johnson Consumer and Personal Products Worldwide · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NeurogesX:

Cite this brief

Drug Landscape (2026). NeurogesX — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neurogesx. Accessed 2026-05-15.

Related